auryxia
auryxia: developed by 1 company · 1 FDA decision. Updated within the last hour.
Development Pipeline (1)
| Company | Phase |
|---|---|
| KERYX BIOPHARMACEUTICALS INC (KERYX) | Approved |
FDA Decisions
Frequently asked questions
Who is developing auryxia?
auryxia is being developed by KERYX BIOPHARMACEUTICALS INC.
What is auryxia's latest FDA decision?
The most recent tracked FDA decision for auryxia is Approval for 1 INDICATIONS AND USAGE Ferric citrate tablets are a phosphate binder indicated for the control of serum phosphorus levels in adult patients with chronic kidney disease on dialysis. ( 1 ) Ferric citrate tablets are an iron replacement product indicated for the treatment of iron deficiency anemia in adult patients with chronic kidney disease not on dialysis. ( 1 ) 1.1 Hyperphosphatemia in Chronic Kidney Disease on Dialysis Ferric citrate tablets are indicated for the control of serum phosphorus levels in adult patients with chronic kidney disease on dialysis. 1.2 Iron Deficiency Anemia in Chronic Kidney Disease Not on Dialysis Ferric citrate tablets are indicated for the treatment of iron deficiency anemia in adult patients with chronic kidney disease not on dialysis., dated September 5, 2014.
Get deeper analysis on auryxia
Full trial data, mechanism of action, competitive landscape, and AI-powered insights.
Start Free Analysis